CTNM

Contineum Therapeutics

• PUBT·05/15 20:05

  Contineum Therapeutics grants 51,000-share inducement stock option to new employee

• Reuters·05/15 20:05

  CONTINEUM THERAPEUTICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

• Dow Jones·05/14 16:56

  Contineum Therapeutics Is Maintained at Equal-Weight by Morgan Stanley

• Benzinga·05/14 16:45

  Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16

• PUBT·05/12 20:05

  Contineum Therapeutics to present at RBC Capital Markets Global Healthcare Conference

• PUBT·05/11 20:06

  Contineum presents PIPE-791 pulmonary fibrosis data at ATS 2026 conference

• TipRanks·05/11 02:39

  Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)

• TipRanks·05/08 17:40

  Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Entrada Therapeutics Inc (TRDA) and Contineum Therapeutics, Inc. Class A (CTNM)

• TipRanks·05/06 12:05

  Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Contineum Therapeutics, Inc. Class A (CTNM) and Exelixis (EXEL)

• TipRanks·05/06 07:10

  Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Contineum Therapeutics, Inc. Class A (CTNM) and Schrodinger (SDGR)

• Seeking Alpha·05/05 21:41

  Contineum Therapeutics GAAP EPS of -$0.39

• Dow Jones·05/05 20:52

  *Contineum Therapeutics 1Q Loss/Shr 39c >CTNM

• Dow Jones·05/05 20:52

  *Contineum Therapeutics Sees Funding Sufficient Through Mid-2029 >CTNM

• Benzinga·05/05 20:48

  Contineum Therapeutics Q1 EPS $(0.39) Beats $(0.51) Estimate

• PUBT·05/05 20:19

  Contineum Q1 FY26 net loss narrows 9.6% to $14.5 million